Kai Ding to Ovarian Neoplasms
This is a "connection" page, showing publications Kai Ding has written about Ovarian Neoplasms.
Connection Strength
1.109
-
Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 11; 155(2):201-206.
Score: 0.109
-
Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis. Mol Cancer Res. 2019 06; 17(6):1378-1390.
Score: 0.105
-
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecol Oncol. 2017 12; 147(3):509-513.
Score: 0.095
-
Factors influencing clinical trial enrollment among ovarian cancer patients. Gynecol Oncol. 2017 09; 146(3):465-469.
Score: 0.094
-
Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecol Oncol. 2017 08; 146(2):268-272.
Score: 0.093
-
MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
Score: 0.093
-
Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. Gynecol Oncol. 2017 04; 145(1):32-36.
Score: 0.090
-
The pro-inflammatory effect of obesity on high grade serous ovarian cancer. Gynecol Oncol. 2016 10; 143(1):40-45.
Score: 0.087
-
Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Gynecol Oncol. 2016 08; 142(2):225-30.
Score: 0.087
-
Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol. 2016 Sep; 57(9):1149-55.
Score: 0.084
-
The survival detriment of venous thromboembolism with epithelial ovarian cancer. Gynecol Oncol. 2014 Jul; 134(1):73-7.
Score: 0.075
-
Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol. 2014 Apr; 133(1):11-5.
Score: 0.075
-
BMI1, a new target of CK2a. Mol Cancer. 2017 03 07; 16(1):56.
Score: 0.023